[{"id":"66bf38b6-9dea-4df8-a339-ddaabf2340cf","acronym":"ATHENA","url":"https://clinicaltrials.gov/study/NCT04856046","created_at":"2021-04-22T20:53:47.939Z","updated_at":"2025-02-25T12:28:04.369Z","phase":"","brief_title":"Detection of Plasma DNA Methylation in Peripheral Blood from Patients with Resectable Liver Cancer","source_id_and_acronym":"NCT04856046 - ATHENA","lead_sponsor":"Mayo Clinic","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 11/06/2021","start_date":" 11/06/2021","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-02-24"},{"id":"506639ea-1f9f-4169-b1e7-f028c834b64f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04870944","created_at":"2021-05-04T12:53:25.071Z","updated_at":"2025-02-25T15:12:04.041Z","phase":"Phase 1/2","brief_title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","source_id_and_acronym":"NCT04870944","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBL0137"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/28/2022","start_date":" 01/28/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"6858793b-66b6-4bd1-8de9-e5db913af128","acronym":"","url":"https://clinicaltrials.gov/study/NCT03533582","created_at":"2021-01-18T17:24:25.522Z","updated_at":"2025-02-25T15:10:48.947Z","phase":"Phase 3","brief_title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","source_id_and_acronym":"NCT03533582","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCB1 • AFP","pipe":" | ","alterations":" AFP elevation","tags":["SMARCB1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 05/24/2018","start_date":" 05/24/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"11565097-46a7-40c4-bd2e-84aac455986c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01638533","created_at":"2021-01-18T07:02:41.766Z","updated_at":"2025-02-25T14:33:33.086Z","phase":"Phase 1","brief_title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","source_id_and_acronym":"NCT01638533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • AFP","pipe":"","alterations":" ","tags":["ER • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/03/2012","start_date":" 08/03/2012","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2025-02-07"},{"id":"5416351c-6e6b-41af-9e81-7fd2a0e36c13","acronym":"GETUG 13","url":"https://clinicaltrials.gov/study/NCT00104676","created_at":"2021-01-18T00:20:19.559Z","updated_at":"2025-02-25T16:35:55.671Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","source_id_and_acronym":"NCT00104676 - GETUG 13","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 11/26/2003","start_date":" 11/26/2003","primary_txt":" Primary completion: 03/29/2012","primary_completion_date":" 03/29/2012","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2025-02-06"},{"id":"b5993f06-cb2c-4080-9676-30541427ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980460","created_at":"2021-01-18T03:49:34.064Z","updated_at":"2025-02-25T16:50:58.740Z","phase":"Phase 3","brief_title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","source_id_and_acronym":"NCT00980460","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • temsirolimus • vincristine • fluorouracil topical • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 236","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-04"},{"id":"e8131917-8177-4dab-b17e-b6a23239adad","acronym":"","url":"https://clinicaltrials.gov/study/NCT06629857","created_at":"2025-02-26T15:03:43.704Z","updated_at":"2025-02-26T15:03:43.704Z","phase":"","brief_title":"A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan","source_id_and_acronym":"NCT06629857","lead_sponsor":"Darul Sehat Hospital","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2024-10-08"},{"id":"4629442d-297c-4cea-ba12-8b6c1e5ff2c5","acronym":"LENVABLA","url":"https://clinicaltrials.gov/study/NCT05113186","created_at":"2021-11-09T12:53:04.452Z","updated_at":"2025-02-25T13:35:59.564Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative","source_id_and_acronym":"NCT05113186 - LENVABLA","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" AFP • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["AFP • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 07/02/2025","primary_completion_date":" 07/02/2025","study_txt":" Completion: 10/02/2026","study_completion_date":" 10/02/2026","last_update_posted":"2024-08-01"},{"id":"2c66d4b7-1c2e-4cd1-a61a-2f452cfb4042","acronym":"","url":"https://clinicaltrials.gov/study/NCT06470464","created_at":"2025-02-26T14:17:59.459Z","updated_at":"2025-02-26T14:17:59.459Z","phase":"Phase 2","brief_title":"Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor","source_id_and_acronym":"NCT06470464","lead_sponsor":"Shandong First Medical University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • epirubicin • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/16/2024","primary_completion_date":" 06/16/2024","study_txt":" Completion: 06/16/2024","study_completion_date":" 06/16/2024","last_update_posted":"2024-06-24"},{"id":"4898b5ad-3c9a-468d-8fed-e1f7bd83f3ff","acronym":"CARVac","url":"https://clinicaltrials.gov/study/NCT04503278","created_at":"2021-05-18T06:52:33.666Z","updated_at":"2025-02-25T16:25:57.832Z","phase":"Phase 1","brief_title":"A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors","source_id_and_acronym":"NCT04503278 - CARVac","lead_sponsor":"BioNTech Cell \u0026 Gene Therapies GmbH","biomarkers":" AFP • CLDN6","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AFP • CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT211"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2040","study_completion_date":" 01/01/2040","last_update_posted":"2024-05-31"},{"id":"0ddf2dab-b38d-4054-a616-48669cd75157","acronym":"","url":"https://clinicaltrials.gov/study/NCT02143401","created_at":"2021-01-18T09:57:19.810Z","updated_at":"2024-07-02T16:35:01.909Z","phase":"Phase 1","brief_title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02143401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • AFP • CASP3","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1 • AFP • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2014","start_date":" 11/07/2014","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2024-05-22"},{"id":"ed745a1a-e25b-481e-9a43-45f739d28d5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04239092","created_at":"2021-01-18T20:36:34.133Z","updated_at":"2024-07-02T16:35:03.671Z","phase":"Phase 1","brief_title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","source_id_and_acronym":"NCT04239092","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • irinotecan • topotecan • elraglusib (9-ING-41) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-15"},{"id":"89dd2a7f-11f6-4dd3-813c-39c7d1f75e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01602666","created_at":"2021-01-18T06:51:17.342Z","updated_at":"2024-07-02T16:35:08.661Z","phase":"Phase 2","brief_title":"Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors","source_id_and_acronym":"NCT01602666","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 06/27/2012","start_date":" 06/27/2012","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-19"},{"id":"7cc580e8-c1f3-4929-85f2-d9ad42d412c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02968810","created_at":"2021-01-18T14:35:38.364Z","updated_at":"2024-07-02T16:35:09.555Z","phase":"Phase 2","brief_title":"Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis","source_id_and_acronym":"NCT02968810","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" ALPL-H","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALPL-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-16"},{"id":"2e1082a5-a1f6-4914-a8d9-c58f5de1c0cb","acronym":"SEMS","url":"https://clinicaltrials.gov/study/NCT02537548","created_at":"2021-01-18T12:16:28.563Z","updated_at":"2024-07-02T16:35:14.218Z","phase":"","brief_title":"Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma","source_id_and_acronym":"NCT02537548 - SEMS","lead_sponsor":"University of Southern California","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 08/28/2015","start_date":" 08/28/2015","primary_txt":" Primary completion: 08/28/2025","primary_completion_date":" 08/28/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2024-03-18"},{"id":"b8abe3c1-ebf1-450d-b2ce-80fa759fca2f","acronym":"LANDMARC","url":"https://clinicaltrials.gov/study/NCT04665388","created_at":"2021-01-19T20:43:31.793Z","updated_at":"2024-07-02T16:35:14.635Z","phase":"","brief_title":"LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers","source_id_and_acronym":"NCT04665388 - LANDMARC","lead_sponsor":"University Health Network, Toronto","biomarkers":" CEACAM5 • AFP","pipe":"","alterations":" ","tags":["CEACAM5 • AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-03-15"},{"id":"47786988-3db5-44b3-967d-c4734087d1e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02908048","created_at":"2021-01-18T14:16:05.856Z","updated_at":"2024-07-02T16:35:14.800Z","phase":"","brief_title":"Extracellular RNA Markers of Liver Disease and Cancer","source_id_and_acronym":"NCT02908048","lead_sponsor":"Mayo Clinic","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1810","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-03-13"},{"id":"532d7c26-0f68-456e-8b5b-0346ea10cb8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04451603","created_at":"2021-01-18T21:24:54.838Z","updated_at":"2024-07-02T16:35:14.901Z","phase":"","brief_title":"LiverMultiScan Analysis of MRI Scans in HCC","source_id_and_acronym":"NCT04451603","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/19/2018","start_date":" 10/19/2018","primary_txt":" Primary completion: 03/16/2021","primary_completion_date":" 03/16/2021","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-03-13"},{"id":"8c6ccd7c-7caf-4ecd-b6bb-188e3be5b07f","acronym":"Liver-NET1","url":"https://clinicaltrials.gov/study/NCT05546879","created_at":"2024-03-13T02:31:40.857Z","updated_at":"2024-07-02T16:35:15.671Z","phase":"Phase 1","brief_title":"Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC","source_id_and_acronym":"NCT05546879 - Liver-NET1","lead_sponsor":"University Hospital, Grenoble","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • NP137"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2025","study_completion_date":" 11/15/2025","last_update_posted":"2024-03-08"},{"id":"2fb170a4-c1bb-478b-9a26-3efad1e342ff","acronym":"ARYA-2","url":"https://clinicaltrials.gov/study/NCT04634357","created_at":"2022-04-24T10:00:30.724Z","updated_at":"2024-07-02T16:35:15.791Z","phase":"Phase 1/2","brief_title":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","source_id_and_acronym":"NCT04634357 - ARYA-2","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ET140203"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/19/2022","start_date":" 07/19/2022","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-03-07"},{"id":"159eb306-61d8-4d15-addb-074ab4a7251b","acronym":"ELEGANCE","url":"https://clinicaltrials.gov/study/NCT04965259","created_at":"2021-07-16T13:53:21.915Z","updated_at":"2024-07-02T16:35:17.099Z","phase":"","brief_title":"Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort (ELEGANCE)","source_id_and_acronym":"NCT04965259 - ELEGANCE","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 02/21/2025","primary_completion_date":" 02/21/2025","study_txt":" Completion: 02/21/2025","study_completion_date":" 02/21/2025","last_update_posted":"2024-02-29"},{"id":"cd334664-b55d-49f3-960b-50fed3f6d9ca","acronym":" AcSé Pembrolizumab study","url":"https://clinicaltrials.gov/study/NCT03012620","created_at":"2021-01-18T14:49:27.880Z","updated_at":"2025-02-25T16:05:41.112Z","phase":"Phase 2","brief_title":"Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012620 -  AcSé Pembrolizumab study","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":" | ","alterations":" PD-L1 underexpression • FASN-L","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • FASN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 12/26/2022","primary_completion_date":" 12/26/2022","study_txt":" Completion: 12/14/2023","study_completion_date":" 12/14/2023","last_update_posted":"2024-02-28"},{"id":"4b5fa737-38c5-463a-9236-f514b088e5af","acronym":"AflacST1502","url":"https://clinicaltrials.gov/study/NCT02574728","created_at":"2021-01-18T12:28:46.275Z","updated_at":"2024-07-02T16:35:17.957Z","phase":"Phase 2","brief_title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors","source_id_and_acronym":"NCT02574728 - AflacST1502","lead_sponsor":"Emory University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-23"},{"id":"732074d1-2ecd-461b-b3f5-f6c12921f34e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04601428","created_at":"2021-01-19T20:30:32.372Z","updated_at":"2025-02-25T16:26:06.755Z","phase":"Phase 1","brief_title":"Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)","source_id_and_acronym":"NCT04601428","lead_sponsor":"Koo Foundation Sun Yat-Sen Cancer Center","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-23"}]